Eli Lilly and Company

Eli Lilly is backing Chai Discovery's $400 million raise at a $3.4 billion valuation, alongside Pfizer. The AI biotech claims 20% hit rates on antibody design, a step toward faster drug development. Lilly's own numbers are strong. Revenue grew 47.4% year over year. EPS jumped 128.8%. Net margin hit 35%. The stock trades at 44.28 times earnings, near the top of its 52-week range of $623.78 to $1249.45. The Alpha Score sits at 68.6, driven by momentum at 80.8 and quality at 87. Value scores lower at 59.8. With earnings growth outpacing revenue, margins are expanding. The next catalyst could be the Chai partnership's progress or the next quarterly report.

Eli Lilly sits near the top of its 52-week range, supported by a momentum score of 89.5 and a quality score of 87 within AlphaScala's framework. Revenue grew 47.4% year over year, while EPS surged 128.8%, pushing net margin to 35%. The P/E of 53.24 reflects the market's willingness to pay up for that growth trajectory. A small but signal-bearing move: Lilly joined the $85 million Series C round for Flare Therapeutics, a biotech targeting transcription factors in cancer. The investment adds pipeline optionality without moving the needle near term. What to watch next quarter: any update on the oral GLP-1 program and whether margin expansion continues at this pace.

Eli Lilly's momentum score of 93.6 reflects a stock that has nearly doubled over the past 52 weeks. The numbers back it up: revenue grew 47.4% year over year, EPS surged 128.8%, and net margin hit 35%. At 53.2 times earnings, the multiple is steep, but growth investors see the pipeline justifying the premium. Quality score of 87 supports the thesis. Sentiment sits at 50, suggesting room for more bullish repricing if upcoming trial readouts or a Tirzepatide label expansion deliver. The next catalyst is the July earnings call, where sales guidance for Mounjaro and Zepbound will steer the stock's path within the current 52W range.

LLY sits at the upper end of its $625–$1,230 range. The P/E of 53 looks rich, but revenue growth of 47% and EPS expansion of 129% support the multiple. Net margins hit 35%, a rare level in pharma. The stock has more than doubled from the 2023 low and shows no sign of rolling over. The Alpha Score of 71.9 is driven by momentum at 89 and quality at 87. Value scores below 55, which is the trade-off for owning a growth leader. Sentiment sits at 50, suggesting no crowding. Next quarter's earnings will be the big test – analysts already expect another beat. The risk is a miss on obesity drug sales, which would pressure the premium fast.

Eli Lilly shares trade near the top of their 52-week range after another quarter of breakneck expansion. Revenue climbed 47.4% year over year, while earnings per share more than doubled—up 128.8%. Net margin reached 35%, a threshold few drugmakers touch. The momentum score sits at 96.2 on a 100-point scale, reflecting the market’s appetite for the company’s metabolic drug franchise. At 53 times trailing earnings, the multiple leaves no room for a stumble. The value score is a middling 54.2, which suggests the stock prices a long runway of future growth. The quality score of 87 supports that bet: strong margins and accelerating EPS growth give the valuation some cover. The next tell will be the upcoming quarterly print, where any slowdown in the Mounjaro or Zepbound trajectory would test the premium.